CHIMERIX INC (CMRX) Stock Price, Forecast & Analysis
USA - NASDAQ:CMRX - US16934W1062 - Common Stock
CMRX Key Statistics, Chart & Performance
The current stock price of CMRX is 8.54 USD. In the past month the price increased by 0.83%. In the past year, price increased by 865.63%.
CMRX Latest News, Press Relases and Analysis
CMRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.59 | 385.18B | ||
| AMGN | AMGEN INC | 13.68 | 160.66B | ||
| GILD | GILEAD SCIENCES INC | 14.63 | 148.64B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.12 | 109.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.48 | 69.08B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 350.8 | 59.78B | ||
| ARGX | ARGENX SE - ADR | 61.77 | 50.39B | ||
| INSM | INSMED INC | N/A | 40.08B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.01 | 34.10B | ||
| NTRA | NATERA INC | N/A | 27.30B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.98B | ||
| BIIB | BIOGEN INC | 9.22 | 22.62B |
Related stock screener links
About CMRX
Company Profile
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Durham, North Carolina and currently employs 79 full-time employees. The company went IPO on 2013-04-11. The firm is focused on developing medicines that address unmet medical needs. The firm's product Imipridones is a cancer therapy that provides ONC201, which is in clinical-stage development for H3 K27M-mutant glioma as its lead indication. In addition, imipridone ONC206 is in dose-escalating clinical trials. Imipridones target specific G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease P (ClpP), resulting in cancer cell death. The firm's product Imipridone chemical scaffold provides an opportunity to target GPCRs and ClpP with differential specificity and function. Its ONC212 is an imipridone, an investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. Its CMX521 is a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. The Chimerix Chemical Library contains over 10,000 heterocyclic ring systems and nucleosides, also includes approximately 3,500 nucleosides.
Company Info
CHIMERIX INC
2505 Meridian Parkway, Suite 100
Durham NORTH CAROLINA 27713 US
CEO: Michael A. Sherman
Employees: 79
Phone: 19198061074
CHIMERIX INC / CMRX FAQ
Can you describe the business of CHIMERIX INC?
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Durham, North Carolina and currently employs 79 full-time employees. The company went IPO on 2013-04-11. The firm is focused on developing medicines that address unmet medical needs. The firm's product Imipridones is a cancer therapy that provides ONC201, which is in clinical-stage development for H3 K27M-mutant glioma as its lead indication. In addition, imipridone ONC206 is in dose-escalating clinical trials. Imipridones target specific G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease P (ClpP), resulting in cancer cell death. The firm's product Imipridone chemical scaffold provides an opportunity to target GPCRs and ClpP with differential specificity and function. Its ONC212 is an imipridone, an investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. Its CMX521 is a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. The Chimerix Chemical Library contains over 10,000 heterocyclic ring systems and nucleosides, also includes approximately 3,500 nucleosides.
Can you provide the latest stock price for CHIMERIX INC?
The current stock price of CMRX is 8.54 USD. The price decreased by -0.12% in the last trading session.
Does CHIMERIX INC pay dividends?
CMRX does not pay a dividend.
How is the ChartMill rating for CHIMERIX INC?
CMRX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Is CHIMERIX INC (CMRX) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CMRX.
What is the employee count for CMRX stock?
CHIMERIX INC (CMRX) currently has 79 employees.
Can you provide the market cap for CHIMERIX INC?
CHIMERIX INC (CMRX) has a market capitalization of 801.05M USD. This makes CMRX a Small Cap stock.
CMRX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CMRX. When comparing the yearly performance of all stocks, CMRX is one of the better performing stocks in the market, outperforming 99.89% of all stocks.
CMRX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to CMRX. CMRX has a great financial health rating, but its profitability evaluates not so good.
CMRX Financial Highlights
Over the last trailing twelve months CMRX reported a non-GAAP Earnings per Share(EPS) of -0.99. The EPS decreased by -7.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -60.54% | ||
| ROE | -72.64% | ||
| Debt/Equity | 0 |
CMRX Forecast & Estimates
11 analysts have analysed CMRX and the average price target is 8.71 USD. This implies a price increase of 2% is expected in the next year compared to the current price of 8.54.
For the next year, analysts expect an EPS growth of 13.8% and a revenue growth 2198.64% for CMRX